Prostaglandin precursor synthesis

Prostaglandin precursor synthesis refers collectively to all biochemical reactions leading from membrane phospholipids—primarily via release of arachidonic acid—to formation of bioactive prostaglandins through sequential enzymatic steps. The initial step involves cleavage by phospholipase A₂, releasing arachidonic acid, which is then converted by cyclooxygenases (COX‑1/PTGS1 & COX‑2/PTGS2) into unstable endoperoxides (PGG₂/PGH₂) that are further processed by various synthases into distinct classes of prostanoids including PGE₂, PGD₂, PGF₂α, PGI₂ (prostacyclin), and thromboxanes[3][6][7]. These molecules regulate diverse physiological processes such as inflammation, vascular tone modulation, platelet aggregation/inhibition, uterine contraction/relaxation—and play major roles in pathophysiology including pain signaling and inflammatory diseases[8]. Therapeutic agents like NSAIDs act on key enzymes within this synthetic route rather than on “the” synthetic process itself; thus “prostaglandin precursor synthesis” should be replaced with precise enzyme targets when discussing drug action or biomarker development[4][6].

Other names

prostaglandin biosynthesisprostaglandin synthesis pathwayarachidonic acid cascade

Inhibition of cyclooxygenase activity blocks conversion of arachidonic acid into prostaglandins. Glucocorticoids block release of arachidonic acid by inhibiting phospholipase A2. These mechanisms reduce downstream prostaglandin-mediated inflammation and pain responses.